Sin conexión a internet: se muestra la versión guardada de la página.

Innate Pharma

FREUR
← Al screener

Innate Pharma (US:IPHYF) — Biotechnology: Biological Products (No Diagnostic Substances). Número de bolsas en las que cotizan las acciones de la empresa: 3. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.

Sobre la empresa

Sitio web
innate-pharma.com
Sector
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Sede central
MARSEILLE, France
Consejero delegado
Jonathan E. Dickinson
Empleados
120
Fundada
1999
Acciones en circulación
111.7 M
Capital flotante
70.45 M
Capitalización bursátil
146.33 M EUR
Insiders
17.46%
Inversores institucionales
10.86%
Industria (SIC)
Biological Products, (No Diagnostic Substances)
ISIN
FR0010331421
FCF
−52.9 M EUR
Deuda
0
Resultados y FCF — para los 12 meses hasta 31.12.2025 (el último informe de la empresa).
Descripción

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.

Bolsas y tickers

BolsaTickerMonedaPrecioTipo
PA Euronext ParisIPH principalEUR1.302 +2.84%acciones ordinarias
LSE London Stock Exchange0EVI IOBEUR1.304 +2.27%acciones ordinarias
US USA StocksIPHYF OTCUSD1.5092 -8.53%acciones ordinarias

Precio en 3 meses

PA:IPH · EUR
US:IPHYF no ha cotizado en los últimos 3 meses; el gráfico muestra PA:IPH
día alcista día bajistaPasa el cursor / toca un día — precios de apertura, cierre, máximo y mínimo

Noticias de esta semana

No hay noticias en la última semana. Últimas noticias: 17.09.2026.

anuncio

Principales accionistas

TitularParticipaciónAccionesFecha del informe
ETF Series Solutions-Ran…0.08%72 6952025-02-28
Lion Point Capital, LP0.07%81 1512026-06-30
Morgan Stanley0.04%43 5242026-06-30
Smartharvest Portfolios,…0.02%23 7502026-06-30
Dimensional ETF Trust-Di…0.02%23 2772026-01-31
Xtx Topco Ltd0.01%15 1302026-06-30
Citadel Advisors Llc0.01%12 4412026-06-30
Jane Street Group, LLC0.01%10 3102026-06-30
Rhumbline Advisers0%4 7192026-06-30
UBS Group AG0%1 3632026-06-30
Farther Finance Advisors…0%212026-06-30
Gamma Investing LLC0%92026-06-30